IL-1 Pathway Inhibition in Recurrent Pericarditis Management
In RESONANCE, IL-1 pathway inhibition increasingly replaced corticosteroids as second-line therapy. Most patients starting corticosteroids transitioned to IL-1 pathway inhibition; few transitioned from second-line IL-1 pathway inhibition to long-term corticosteroids. These findings may inform treatment algorithms and patient-provider decision-making.
Authors
- Paul C Cremer (ORCID: https://orcid.org/0000-0002-0794-3306)
- JoAnn Clair (ORCID: https://orcid.org/0000-0003-0281-1651)
- Allison Curtis (ORCID: https://orcid.org/0009-0003-9596-2236)
- Sushil Allen Luis (ORCID: https://orcid.org/0000-0001-9821-1225)
- Vidhya Parameswaran (ORCID: https://orcid.org/0000-0001-8461-1797)
- John F. Paolini (ORCID: https://orcid.org/0000-0001-7622-8851)
- Brittany Weber (ORCID: https://orcid.org/0000-0002-0177-2091)
- Michael Garshick (ORCID: https://orcid.org/0000-0002-6649-3755)
- Dona Winnowski
- Ajit Raisinghani
- Allan Klein
Institutions
- Northwestern University (US)
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- Harvard University (US)
- University of California San Diego (US)
- Canadian Arthritis Patient Alliance (CA)
- Cubist Pharmaceuticals (United States) (US)
Publication Details
- Journal
- JACC Advances
- Published
- 2025-08-15
- DOI
- https://doi.org/10.1016/j.jacadv.2025.102050
- Citations
- 1
- Primary Topic
- Pericarditis and Cardiac Tamponade
- Type
- article
- Field-Weighted Citation Impact
- 1.39